BiomX Inc. (PHGE)
NYSEAMERICAN: PHGE · Real-Time Price · USD
0.4800
-0.0757 (-13.62%)
Apr 1, 2025, 9:30 AM EST - Market open

Company Description

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease.

It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.

The company’s product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials.

BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

BiomX Inc.
BiomX logo
Country Israel
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 57
CEO Jonathan Solomon

Contact Details

Address:
22 Einstein Street, Floor 4
Ness Ziona, 7414003
Israel
Phone 972 7 2394 2377
Website biomx.com

Stock Details

Ticker Symbol PHGE
Exchange NYSEAMERICAN
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001739174
CUSIP Number 09090D103
ISIN Number US09090D1037
Employer ID 82-3364020
SIC Code 2836

Key Executives

Name Position
Jonathan Eitan Solomon MBA Chief Executive Officer and Director
Marina Wolfson CPA Chief Financial Officer and Secretary
Dr. Merav Bassan Ph.D. Chief Development Officer
Prof. Rotem Sorek Ph.D. Scientific Founder
Dr. Eran Elinav M.D., Ph.D. Scientific Founder
Dr. Timothy K. Lu M.D., Ph.D. Scientific Founder
Inbal Benjamini-Elran C.H.R.O

Latest SEC Filings

Date Type Title
Apr 1, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 31, 2025 8-K Current Report
Mar 27, 2025 DEF 14A Other definitive proxy statements
Mar 25, 2025 10-K Annual Report
Mar 25, 2025 8-K Current Report
Mar 17, 2025 PRE 14A Other preliminary proxy statements
Mar 5, 2025 8-K Current Report
Mar 4, 2025 SCHEDULE 13G/A Filing
Mar 3, 2025 SCHEDULE 13D/A Filing
Feb 27, 2025 8-K Current Report